Related references
Note: Only part of the references are listed.Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial
Vlad Ratziu et al.
GASTROENTEROLOGY (2008)
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis
Guruprasad P. Aithal et al.
GASTROENTEROLOGY (2008)
Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease
Janus P. Ong et al.
JOURNAL OF HEPATOLOGY (2008)
Thiazolidinediones and cardiovascular outcomes in older patients with diabetes
Lorraine L. Lipscombe et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis
Glen Lutchman et al.
HEPATOLOGY (2007)
Rosiglitazone evaluated for cardiovascular outcomes - An interim analysis
Philip D. Home et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Renata Belfort et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Mattias Ekstedt et al.
HEPATOLOGY (2006)
Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats
I. A. Leclercq et al.
GUT (2006)
Insulin resistance: A metabolic pathway to chronic liver disease
E Bugianesi et al.
HEPATOLOGY (2005)
The natural history of nonalcoholic fatty liver disease: A population-based cohort study
LA Adams et al.
GASTROENTEROLOGY (2005)
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
DE Kleiner et al.
HEPATOLOGY (2005)
A Pilot Study of Vitamin E Versus Vitamin E and Pioglitazone for the Treatment of Nonalcoholic Steatohepatitis
Arun J. Sanyal et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
A pilot study of ploglitazone treatment for nonalcoholic steatohepatitis
K Promrat et al.
HEPATOLOGY (2004)
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone
BA Neuschwander-Tetri et al.
HEPATOLOGY (2003)
Sensitivity effect of rosiglitazone on insulin and body composition in type 2 diabetic patients
DG Carey et al.
OBESITY RESEARCH (2002)
Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro
A Galli et al.
GASTROENTEROLOGY (2002)
Medical progress - Nonalcoholic fatty liver disease
P Angulo
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Rosiglitazone - A review of its use in the management of type 2 diabetes mellitus
AJ Wagstaff et al.
DRUGS (2002)
Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes
LS Phillips et al.
DIABETES CARE (2001)
Ligands of peroxisome proliferator-activated receptor γ modulate profibrogenic and proinflammatory actions in hepatic stellate cells
F Marra et al.
GASTROENTEROLOGY (2000)
Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus - A randomized controlled trial
V Fonseca et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetes
P Raskin et al.
DIABETOLOGIA (2000)
Peroxisome proliferator-activated receptor gamma transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells
A Galli et al.
HEPATOLOGY (2000)
Share Paper
